AI in the Pharma Industry: Top Pharmaceutical Companies Using AI

Here's the list of the top pharmaceutical companies using AI or machine learning for drug discovery, clinical research etc.



In the modern world, we are all surrounded by AI. There are many examples of AI which we are using whether knowingly or unknowingly in our day-to-day life. For example, social media, search engines, product recommendations, Email filters, etc. With the fourth industrial revolution AI has taken over the world and the pharmaceutical and healthcare sector are most affected industries by AI. This article lists the top pharmaceutical companies using AI or machine learning for drug discovery, clinical research, disease diagnosis, novel medication, predictions, data analysis, etc.



Pfizer is an American multinational pharmaceutical corporation, and one of the world’s 2019s largest pharmaceutical companies. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology. In 2019, Pfizer announced a partnership with Concreto Health AI, to advance the work in Precision Oncology using Artificial Intelligence and real-world data. By combining Pfizer’s real-world data with Artificial Intelligence and data science, the company aims to identify new and more precise treatment options, completely redefine study designs, and speed up the completion time of the outcomes studies.


Janssen Pharmaceutica

Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium, and is part of the Johnson & Johnson family of companies. In 2019, Janssen announced a collaboration with a French startup to develop an AI-powered drug design system. The AI startup will develop an in silico system, based on neural network models called deep generative models. Based on its capacity to explore chemical space (the space covering all possible molecules and chemical compounds) with speed and efficiency, the new Artificial Intelligence system should enable the identification of molecules that meet the desired criteria in each research project.



Sanofi is a French multinational pharmaceutical company headquartered in Paris, France. The company works in the field of development, manufacturing, and marketing of pharmaceutical drugs. Sanofi covers seven major therapeutic areas like the cardiovascular, central nervous system, diabetes, oncology, internal medicine, thrombosis, and vaccines. In 2018, Sanofi partnered with an AI startup to build an AI solution that would automate medical literature reviews. After the three-month pilot project of the new AI solution, Sanofi recognized that utilizing Artificial Intelligence software reduced the review time from 13 minutes per paper to about one second per paper.



Novartis is a Swiss multinational pharmaceutical company based in Basel, Switzerland. In September 2019, Novartis and Microsoft announced a multiyear partnership that will leverage data and Artificial Intelligence to transform how medicines are discovered, developed, and commercialized. The strategic collaboration will focus on two core objectives: AI Empowerment and AI Exploration. Novartis aims to address some of the biggest challenges facing the pharmaceutical industry today, by bringing AI expertise to every employee so they can work to discover new medicines at scale and reduce costs.



Bayer is a German multinational pharmaceutical and life science company, with headquarters in Leverkusen, Germany. In January 2020, Bayer partnered with a UK-based AI-driven drug discovery company to a multi-target collaboration. The two companies will work on early research projects using the AI drug discovery platform and Bayer’s large amount of data. They aim to identify and optimize novel lead structures for potential drug candidates to treat cardiovascular and oncological diseases. The AI collaboration has the potential to accelerate drug discovery and improve drug development productivity in terms of quality, cost, and by reducing the time of the drug discovery and development cycle.



Roche has developed machine learning diagnostic techniques for diabetic macular edema, a complication of diabetes that causes a thickening of the retina and leads to blindness. Roche can utilize its vast clinical trial database to develop AI algorithms to predict the presence of disease, risk of disease progression, and response to treatment; all of which could be supplied to ophthalmologists to deliver higher quality personalized healthcare.



Abbvie is working with Artificial Intelligence very silently. But it does have a confidential project listed with Atomwise. In September 2016, AbbVie partnered with AiCure to use an AI-based patient monitoring platform to improve adherence in an AbbVie phase 2 schizophrenia trial.



Amgen is an investor in precision medicine startup GNS Healthcare. In May 2018, MIT announced that Amgen was a member of its Machine Learning for Pharmaceutical Discovery and Synthesis Consortium. Amgen is also working with medical research machine learning startup Owkin. Amgen is also a member of MELLODDY (Machine Learning Ledger Orchestration for Drug Discovery) project which will train machine learning models on datasets from multiple partners while ensuring the privacy of each partner using federated learning.


Gilead Sciences

Gilead’s first publicly announced use of AI in drug discovery was in April 2019. This month, Gilead announced a strategic collaboration with stealthy startup Insitro. The collaboration will focus on nonalcoholic steatohepatitis (NASH). Gilead will use Insitro’s platform to create disease models for NASH and find targets that affect the disease’s progression and regression.